Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Francesco Pepe, Gianluca Russo, Mariantonia Nacchio, Francesca Ambrosio, Roberto Bianco, Severo Campione, Alessandro Caputo, Pietro Carotenuto, Antonio D'Antonio, Maria D'Armiento, Vincenzo Damiano, Bruno Daniele, Giovanni De Chiara, Marco De Felice, Luigi Della Gravara, Teresa Fabozzi, Salvatore Feliciano, Cesare Gridelli, Elia Guadagno, Gennaro Ilardi, Davide Leopardo, Annamaria Libroia, Paolo Maione, Floriana Morgillo, Jessica Orefice, Luigi Panico, Danilo Rocco, Alberto Servetto, Silvia Varricchio, Pio Zeppa, Elena Vigliar, Claudio Bellevicine, Giancarlo Troncone, Umberto Malapelle
{"title":"非小细胞肺癌患者基于rna的新一代测序：来自意大利坎帕尼亚的数据","authors":"Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Francesco Pepe, Gianluca Russo, Mariantonia Nacchio, Francesca Ambrosio, Roberto Bianco, Severo Campione, Alessandro Caputo, Pietro Carotenuto, Antonio D'Antonio, Maria D'Armiento, Vincenzo Damiano, Bruno Daniele, Giovanni De Chiara, Marco De Felice, Luigi Della Gravara, Teresa Fabozzi, Salvatore Feliciano, Cesare Gridelli, Elia Guadagno, Gennaro Ilardi, Davide Leopardo, Annamaria Libroia, Paolo Maione, Floriana Morgillo, Jessica Orefice, Luigi Panico, Danilo Rocco, Alberto Servetto, Silvia Varricchio, Pio Zeppa, Elena Vigliar, Claudio Bellevicine, Giancarlo Troncone, Umberto Malapelle","doi":"10.32074/1591-951X-1015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations represent fundamental predictive biomarkers for advanced non-small cell lung cancer (NSCLC) patients to ensure the best treatment choice. In this scenario, RNA-based NGS approach has emerged as an extremely useful tool for detecting these alterations. In this study, we report our NGS molecular records on ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations detected by using a narrow RNA-based NGS panel, namely SiRe fusion.</p><p><strong>Methods: </strong>We retrospectively reviewed data on 201 advanced stage NSCLC patients who were referred to our laboratory for RNA-based molecular evaluation of ALK, ROS1, RET, NTRK gene rearrangements as well as MET exon 14 skipping.</p><p><strong>Results: </strong>Overall, 23 (11.4%) positive cases were retrieved. Regarding molecular assessment, 11 (5.5%), 2 (1.0%), 9 (4.5%), and 1 (0.5%) out of 201 harbored an ALK, ROS1, RET gene rearrangement, or MET exon 14 skipping, respectively.</p><p><strong>Conclusions: </strong>In this study, we provide real-world experience on RNA-based NGS analysis in patients with advanced stage NSCLC.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"116 5","pages":"310-319"},"PeriodicalIF":4.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.\",\"authors\":\"Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Francesco Pepe, Gianluca Russo, Mariantonia Nacchio, Francesca Ambrosio, Roberto Bianco, Severo Campione, Alessandro Caputo, Pietro Carotenuto, Antonio D'Antonio, Maria D'Armiento, Vincenzo Damiano, Bruno Daniele, Giovanni De Chiara, Marco De Felice, Luigi Della Gravara, Teresa Fabozzi, Salvatore Feliciano, Cesare Gridelli, Elia Guadagno, Gennaro Ilardi, Davide Leopardo, Annamaria Libroia, Paolo Maione, Floriana Morgillo, Jessica Orefice, Luigi Panico, Danilo Rocco, Alberto Servetto, Silvia Varricchio, Pio Zeppa, Elena Vigliar, Claudio Bellevicine, Giancarlo Troncone, Umberto Malapelle\",\"doi\":\"10.32074/1591-951X-1015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations represent fundamental predictive biomarkers for advanced non-small cell lung cancer (NSCLC) patients to ensure the best treatment choice. In this scenario, RNA-based NGS approach has emerged as an extremely useful tool for detecting these alterations. In this study, we report our NGS molecular records on ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations detected by using a narrow RNA-based NGS panel, namely SiRe fusion.</p><p><strong>Methods: </strong>We retrospectively reviewed data on 201 advanced stage NSCLC patients who were referred to our laboratory for RNA-based molecular evaluation of ALK, ROS1, RET, NTRK gene rearrangements as well as MET exon 14 skipping.</p><p><strong>Results: </strong>Overall, 23 (11.4%) positive cases were retrieved. Regarding molecular assessment, 11 (5.5%), 2 (1.0%), 9 (4.5%), and 1 (0.5%) out of 201 harbored an ALK, ROS1, RET gene rearrangement, or MET exon 14 skipping, respectively.</p><p><strong>Conclusions: </strong>In this study, we provide real-world experience on RNA-based NGS analysis in patients with advanced stage NSCLC.</p>\",\"PeriodicalId\":45893,\"journal\":{\"name\":\"PATHOLOGICA\",\"volume\":\"116 5\",\"pages\":\"310-319\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PATHOLOGICA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32074/1591-951X-1015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-1015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.
Objective: ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations represent fundamental predictive biomarkers for advanced non-small cell lung cancer (NSCLC) patients to ensure the best treatment choice. In this scenario, RNA-based NGS approach has emerged as an extremely useful tool for detecting these alterations. In this study, we report our NGS molecular records on ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations detected by using a narrow RNA-based NGS panel, namely SiRe fusion.
Methods: We retrospectively reviewed data on 201 advanced stage NSCLC patients who were referred to our laboratory for RNA-based molecular evaluation of ALK, ROS1, RET, NTRK gene rearrangements as well as MET exon 14 skipping.
Results: Overall, 23 (11.4%) positive cases were retrieved. Regarding molecular assessment, 11 (5.5%), 2 (1.0%), 9 (4.5%), and 1 (0.5%) out of 201 harbored an ALK, ROS1, RET gene rearrangement, or MET exon 14 skipping, respectively.
Conclusions: In this study, we provide real-world experience on RNA-based NGS analysis in patients with advanced stage NSCLC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
